

Emerging Gene Therapy Treatments for Inherited Retinal Diseases

Guest Editor:

Dr. Livia S Carvalho

Lions Eye Institute, University of
Western Australia, Nedlands, WA,
Australia

Deadline for manuscript
submissions:

closed (10 July 2022)

Message from the Guest Editor


Dear Colleagues,

With over 270 genes known to be involved in inherited retinal diseases (IRDs), translation of treatment strategies into clinical applications has been historically difficult. However, in recent years, there has been significant advances in basic research findings, including the development of several disease models, as well as translational studies focusing on gene therapy approaches, culminating in an increasing number of ongoing gene therapy clinical trials for inherited retinal diseases. The recent approval of Luxtruna® for Leber congenital amaurosis type 2 (LCA2) has established a clinical grounding and the safety of AAV-based gene therapies. However, with the recent advances of several new technologies, such as gene editing, antisense oligonucleotides and non-viral vectors, we need to start thinking about what we want the retinal gene therapy field to look like moving forward. This Special Issue of the *Journal of Personalized Medicine* aims to highlight the current state of the field and highlight some of the latest advances and technologies that are currently being evaluated to treat vision loss in IRDs.

Dr. Livia S Carvalho

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)